offers 2023 Universal Registration Documents

PARIS–(BUSINESS WIRE)–Supervision News:

CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, designed to treat patients with advanced biventricular heart failure (i.e. company or kamat), today announced the release of the company’s Universal Registration Document (URD) ​​for the year ending December 31, 2023.

The document has been filed with the French Stock Market Authority (Financial Markets Authority) will be open to the public free of charge on request on April 30, 2023 in accordance with current legal provisions; as well as the “Investors/Documents” section of the company's website and the section of the AMF (

It includes in particular the 2023 annual financial report, corporate governance report, required information related to the share buyback program, as well as the statutory auditors' report and information on fees paid to the statutory auditors in 2023. For the convenience of English-speaking readers, CARMAT has provided a free English translation of the 2023 Financial Statements1, which can be viewed on the English section of its website.

— — —

About Kamat

CARMAT is a French medical technology company that designs, manufactures and sells the Aeson ® artificial heart. The company's goal is to make Aeson® the first alternative to heart transplantation, thereby providing a therapeutic solution for patients with end-stage biventricular heart failure who are facing a well-known shortage of available human transplants. Aeson ® is the world's first physiological artificial heart with high blood compatibility, pulsatile and self-regulating functions, saving the lives of thousands of patients awaiting heart transplants each year. The device provides patients with improved quality of life and mobility thanks to its ergonomic, portable external power system that is continuously connected to the implanted prosthetic limb. Aeson ® is already marketed as a bridge to the EU and other countries that recognize the CE mark. Aeson ® is also currently being evaluated within the framework of an Early Feasibility Study (EFS) in the United States. CARMAT was founded in 2008 and is headquartered in the Paris region, with its headquarters in Vélizy-Villacoublay and its production base in Bois-d'Arcy. The company can rely on the talent and expertise of a multidisciplinary team of approximately 200 highly specialized personnel. CARMAT is listed on the Euronext Paris Growth Market (ticker: ALCAR / ISIN: FR0010907956).

3rd party advertising. Not an offer or recommendation by disclosures here or
Remove ads

For more information, please visit and follow us on LinkedIn.

Name: kamat
ISIN code: FR0010907956
Stock code: Alka


This press release and the information contained therein do not constitute an offer to sell or subscribe for CARMAT shares in any country, nor do they constitute a solicitation of an order to buy or subscribe for CARMAT shares. This press release may contain forward-looking statements by the Company regarding its objectives and prospects. These forward-looking statements are based on the company's management's current estimates and expectations and are subject to risk factors and uncertainties, such as the company's ability to implement its strategy, the pace of development of CARMAT production and sales, the pace and results of CARMAT production and sales . ongoing or planned clinical trials, technological evolution and the competitive environment, regulatory changes, industry risks and all risks associated with managing a company's growth. As a result of these or other risk factors and uncertainties, the Company's objectives stated in this press release may not be achieved.

The Company's significant and specific risks are those described in its general registration documents filed with the French Authority de la Financial Markets (Financial Markets Authority – this AMF), numbered D.23-0374. Of particular interest to readers is that the company's current cash runway is limited to mid-May 2024.

Aeson ® is an active implantable medical device available for sale in the European Union and other countries that recognize the CE mark. The Aeson ® Total Artificial Heart is designed to replace the ventricles of a native heart and is considered to be effective in patients with end-stage biventricular heart failure (INTERMACS Classes 1-4) who are unable to benefit from, or will not benefit from, maximal medical therapy. transplant bridge. Implantation decisions and surgical procedures must be performed by a manufacturer-trained healthcare professional. The documentation (Clinician's Manual, Patient's Manual and Alert Manual) should be read carefully to understand the functionality of Aeson ® and the information required for patient selection and correct use (contraindications, precautions, side effects). In the United States, Aeson ® is currently only available as part of an early stage feasibility study approved by the U.S. Food and Drug Administration (FDA).

3rd party advertising. Not an offer or recommendation by disclosures here or
Remove ads

1 Corresponds to URD section 3.2.

Stefan Piatt

Pascal Dabonneau
chief financial officer
Phone: +33 1 39 45 64 50

Elize RP
press relations

caroline carmagno
Phone: +33 6 64 18 99 59

new capital
financial communication
& Investor Relations

Dusan Oresansky
Jeremy Diggle
Phone: +33 1 44 71 94 92

Source: CARMAT

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *